These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28337673)

  • 1. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
    Michiels S; Saad ED; Buyse M
    Drugs; 2017 May; 77(7):713-719. PubMed ID: 28337673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
    Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.
    Rotolo F; Pignon JP; Bourhis J; Marguet S; Leclercq J; Tong Ng W; Ma J; Chan AT; Huang PY; Zhu G; Chua DT; Chen Y; Mai HQ; Kwong DL; Soong YL; Moon J; Tung Y; Chi KH; Fountzilas G; Zhang L; Hui EP; Lee AW; Blanchard P; Michiels S;
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 27927756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.
    Woodford R; Zhou D; Kok PS; Lord SJ; Friedlander M; Marschner I; Simes RJ; Lee CK
    JCO Precis Oncol; 2024 Jan; 8():e2300296. PubMed ID: 38207226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.
    Cheema PK; Burkes RL
    Curr Oncol; 2013 Apr; 20(2):e150-60. PubMed ID: 23559882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer.
    Gharzai LA; Jiang R; Jaworski EM; Morales Rivera K; Dess RT; Jackson WC; Hartman HE; Mehra R; Kishan AU; Solanki AA; Schaeffer EM; Feng FY; Zaorsky NG; Berlin A; Ponsky L; Shoag J; Sun Y; Schipper MJ; Garcia J; Spratt DE
    NEJM Evid; 2023 Apr; 2(4):EVIDoa2200195. PubMed ID: 38320030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
    Oxnard GR; Morris MJ; Hodi FS; Baker LH; Kris MG; Venook AP; Schwartz LH
    J Natl Cancer Inst; 2012 Oct; 104(20):1534-41. PubMed ID: 22927506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls.
    Wright K; Mittal A; Gyawali B
    Curr Opin Oncol; 2023 Nov; 35(6):513-521. PubMed ID: 37621175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting.
    Postmus D; Litiere S; Bogaerts J; Versluis J; Cornelissen JJ; Pignatti F
    Eur J Cancer; 2024 Jan; 197():113496. PubMed ID: 38134481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
    Del Paggio JC; Berry JS; Hopman WM; Eisenhauer EA; Prasad V; Gyawali B; Booth CM
    JAMA Oncol; 2021 May; 7(5):728-734. PubMed ID: 33764385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement.
    Villaruz LC; Socinski MA
    Clin Cancer Res; 2013 May; 19(10):2629-36. PubMed ID: 23669423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An audit strategy for progression-free survival.
    Dodd LE; Korn EL; Freidlin B; Gray R; Bhattacharya S
    Biometrics; 2011 Sep; 67(3):1092-9. PubMed ID: 21210772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed.
    Walia A; Tuia J; Prasad V
    Nat Rev Clin Oncol; 2023 Dec; 20(12):885-895. PubMed ID: 37828154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Starting and stopping cancer drugs: The need for randomized trials.
    Benjamin DJ; Prasad V
    J Cancer Policy; 2023 Dec; 38():100451. PubMed ID: 37918654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PubPredict: Prediction of progression and survival in oncology leveraging publications and early efficacy data.
    Zhang J; Guo Y; Zhou J; Rasmussen HE
    Pharm Stat; 2023; 22(5):963-973. PubMed ID: 37439295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic Disease.
    Freidlin B; Korde LA; Korn EL
    J Clin Oncol; 2023 Oct; 41(29):4616-4620. PubMed ID: 37471685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surrogate end points and their role in clinical trial.
    Indian J Pharmacol; 2009 Feb; 41(1):54. PubMed ID: 20177585
    [No Abstract]   [Full Text] [Related]  

  • 18. Center Volume: The Easy to Measure Imperfect Surrogate.
    Del Nido PJ
    Ann Thorac Surg; 2023 Dec; 116(6):1240. PubMed ID: 37734643
    [No Abstract]   [Full Text] [Related]  

  • 19. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
    Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
    Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
    Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
    Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.